Wolfe Research downgraded Tenet Healthcare (THC) to Peer Perform from Outperform without a price target The firm cites the potential for healthcare exchange pressure in 2026 and provider tax pressure in 2028 and beyond for the downgrade. Wolfe now sees a less compelling risk/reward for the shares amid Tenet’s legislative pressure.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target lowered to $167 from $195 at Baird
- Tenet Healthcare’s Strong Financial Performance and Strategic Initiatives Drive Buy Rating
- Tenet Healthcare price target lowered to $208 from $215 at Barclays
- Bill would force hospitals to warn if not equipped to save preemies, WSJ says
- Tenet Healthcare price target raised to $200 from $185 at Raymond James